Articles tagged with Plasma Cells
Researchers identified a protein called Myb that creates long-term immunity by preserving antibody-producing plasma cells in the bone marrow. The discovery could lead to developing lasting immunity against diseases like malaria.
A mechanism regulating plasma cell lifespan has been elucidated, identifying a promising new biomarker sBCMA for monitoring autoimmune diseases. The study shows that BCMA shedding is correlated with disease severity in multiple sclerosis and lupus patients.
Australian researchers have discovered a group of rogue germinal centre B cells that trigger autoimmune disease. The molecular 'trigger guard' FAS prevents their development, but mutations can lead to autoantibody production and severe immune responses. High levels of IgE antibodies are found in patients with Autoimmune Lymphoprolifera...
Researchers identified a modified host protein as a potential risk factor for plasma cell dyscrasis. Individuals with high levels of SUMO-modified HSP90 are at increased risk of developing multiple myeloma and other related diseases.
Scientists from A*STAR's Bioprocessing Technology Institute uncover crucial role of DOK3 and SHP1 in plasma cell development and production. This discovery advances understanding of plasma cells and antibody response, potentially leading to improved treatment for patients with autoimmune diseases like lupus and multiple myeloma.
Associate Professor David Tarlinton will receive $1 million funding to study immune cells causing lupus. He aims to develop treatments that prevent or reverse the disease by inhibiting harmful antibody production.
Scientists at Emory Vaccine Center found that IL-21 is necessary for long-lasting antibody responses in mice against viral infections. The molecule stimulates germinal centers and supports T helper cells, leading to the generation of virus-specific long-lived plasma cells.
Researchers have identified a substance that prevents fluid accumulation and edema formation in the body, offering new hope for treating excessive fluid retention in patients with chronic heart failure. The discovery also reveals a new molecular mechanism controlling water homeostasis in the kidneys.
The discovery of the Mcl-1 gene's critical role in keeping antibody-producing cells alive could lead to better treatments for diseases like myeloma and chronic immune disorders. Without this gene, plasma cells die within two days.
Researchers have solved the atomic structure of closed plasminogen, a key player in the clot-busting process, revealing an 'Achilles' heel' that proteins bind to when it opens up. This discovery may lead to more effective clot-busting drugs for treating heart attacks and strokes.
Researchers discovered that intestinal B cells acquire functions allowing them to neutralize pathogens while in the gut, a complex balance between beneficial and harmful bacteria. This finding provides insight into the immune system's ability to fight infection without damaging beneficial bacteria and other essential cells.
Researchers at Humabs BioMed SA have discovered the first antibody to target all 16 hemagglutinin subtypes of influenza A, representing a promising treatment option for severe cases of flu. The novel monoclonal antibody, FI6, has been shown to protect mice and ferrets from infection by influenza A virus using multiple mechanisms.
Researchers found plasma cells regulate immune response by negatively impacting follicular helper T cells. The discovery has implications for vaccine administration and autoimmunity.
Researchers found that patients with primary biliary cirrhosis predominantly express IgM in plasma cells, which can be used to distinguish the condition from autoimmune hepatitis. The study supports the use of IgM/IgG ratio as a diagnostic tool for PBC.
Researchers discovered that bortezomib is effective in treating rejection episodes caused by antibodies targeting transplanted kidneys. The study found prompt rejection reversal, prolonged reductions in antibody levels, and improved organ function with suppression of recurrent rejection for at least five months.
The ECOG E4A03 study found that Revlimid plus low-dose dexamethasone improved three-year overall survival rates to 75% in the intent-to-treat population. Continuous therapy also achieved a 91% overall response rate with a high complete response and very good partial response rate.
A landmark analysis found that continuous treatment with Revlimid and dexamethasone improved overall survival and time to disease progression in multiple myeloma patients. Patients who continued therapy had significantly longer overall survival rates compared to those who discontinued treatment after 10 months or less.
Researchers have developed a novel gene delivery approach that targets smooth muscle cells in blood vessels, offering a new paradigm for cell-specific gene delivery. The approach uses an electric field to transiently permeabilize plasma membranes and a specific DNA sequence to control nuclear entry.
Researchers develop new process to identify and clone human antibodies tailored to fight specific infections, offering rapid and effective treatments for influenza and other diseases. The technology has the potential to provide therapy for existing infections or passive immunity against future infection.
A new Mayo Clinic study presents a chromosome test called 'FISH' as a better method for identifying genetic abnormalities in patients with plasma cell malignancies. This improved analysis may help physicians assess patient prognosis and treatment response more accurately.
The malaria parasite affects antigen-presenting dendritic cells in mice, reducing their ability to activate helper T cells and produce cytokines. This impairment leads to the failure of B-cell activation and antibody production, compromising the immune system's response to infection.
Researchers identify a key pathway for targeting pDC function in HIV vaccine development. A decrease in blood pDC frequency is observed in chronic HIV infections, correlating with high viral load and reduced CD4 counts.
Babies who received reconstituted blood during heart surgery had shorter ICU stays (70.5 hours vs 97 hours) and spent less time on mechanical ventilation (36.3 hours vs 53 hours). The study, published in the New England Journal of Medicine, puts to rest a decades-long debate and could save patients and blood banks money.
Researchers at Brigham and Women's Hospital have developed a strategy using small interfering RNA to enhance cancer treatment in cases of drug resistance. They tested their theory in a form of leukemia that is resistant to commonly used anti-cancer drugs.
Researchers at Johns Hopkins Medicine discovered a rare stem cell in multiple myeloma that gives rise to malignant bone marrow plasma cells. Current treatments may not be effective against this errant stem cell, leading scientists to explore dual-therapy approaches to target both the visible and root causes of the disease.
A novel immunoassay for FLC molecules has been developed and assessed for its sensitivity, latex-enhancement, and turbidimetric techniques. The new assay improves upon existing clinical laboratory tests for FLCs in identifying and monitoring patients with multiple myeloma and other diseases.
Researchers have developed a method to 'censor' self-specific B cells, which can help treat autoimmune diseases. This approach may lead to more effective treatments for conditions such as rheumatoid arthritis and lupus.